280 research outputs found
Optimized Broadcast for Deep Learning Workloads on Dense-GPU InfiniBand Clusters: MPI or NCCL?
Dense Multi-GPU systems have recently gained a lot of attention in the HPC
arena. Traditionally, MPI runtimes have been primarily designed for clusters
with a large number of nodes. However, with the advent of MPI+CUDA applications
and CUDA-Aware MPI runtimes like MVAPICH2 and OpenMPI, it has become important
to address efficient communication schemes for such dense Multi-GPU nodes. This
coupled with new application workloads brought forward by Deep Learning
frameworks like Caffe and Microsoft CNTK pose additional design constraints due
to very large message communication of GPU buffers during the training phase.
In this context, special-purpose libraries like NVIDIA NCCL have been proposed
for GPU-based collective communication on dense GPU systems. In this paper, we
propose a pipelined chain (ring) design for the MPI_Bcast collective operation
along with an enhanced collective tuning framework in MVAPICH2-GDR that enables
efficient intra-/inter-node multi-GPU communication. We present an in-depth
performance landscape for the proposed MPI_Bcast schemes along with a
comparative analysis of NVIDIA NCCL Broadcast and NCCL-based MPI_Bcast. The
proposed designs for MVAPICH2-GDR enable up to 14X and 16.6X improvement,
compared to NCCL-based solutions, for intra- and inter-node broadcast latency,
respectively. In addition, the proposed designs provide up to 7% improvement
over NCCL-based solutions for data parallel training of the VGG network on 128
GPUs using Microsoft CNTK.Comment: 8 pages, 3 figure
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
Genomic alterations in metastatic prostate cancer remain incompletely characterized. Here we analyse 493 prostate cancer cases from the TCGA database and perform whole-genome plasma sequencing on 95 plasma samples derived from 43 patients with metastatic prostate cancer. From these samples, we identify established driver aberrations in a cancer-related gene in nearly all cases (97.7%), including driver gene fusions (TMPRSS2:ERG), driver focal deletions (PTEN, RYBP and SHQ1) and driver amplifications (AR and MYC). In serial plasma analyses, we observe changes in focal amplifications in 40% of cases. The mean time interval between new amplifications was 26.4 weeks (range: 5–52 weeks), suggesting that they represent rapid adaptations to selection pressure. An increase in neuron-specific enolase is accompanied by clonal pattern changes in the tumour genome, most consistent with subclonal diversification of the tumour. Our findings suggest a high plasticity of prostate cancer genomes with newly occurring focal amplifications as a driving force in progression
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
Objective Precision oncology depends on translating molecular data into therapy recommendations. However, with the growing complexity of next-generation sequencing-based tests, clinical interpretation of somatic genomic mutations has evolved into a formidable task. Here, we compared the performance of three commercial clinical decision support tools, that is, NAVIFY Mutation Profiler (NAVIFY; Roche), QIAGEN Clinical Insight (QCI) Interpret (QIAGEN) and CureMatch Bionov (CureMatch). Methods In order to obtain the current status of the respective tumour genome, we analysed cell-free DNA from patients with metastatic breast, colorectal or non-small cell lung cancer. We evaluated somatic copy number alterations and in parallel applied a 77-gene panel (AVENIO ctDNA Expanded Panel). We then assessed the concordance of tier classification approaches between NAVIFY and QCI and compared the strategies to determine actionability among all three platforms. Finally, we quantified the alignment of treatment suggestions across all decision tools. Results Each platform varied in its mode of variant classification and strategy for identifying druggable targets and clinical trials, which resulted in major discrepancies. Even the frequency of concordant actionable events for tier I-A or tier I-B classifications was only 4.3%, 9.5% and 28.4% when comparing NAVIFY with QCI, NAVIFY with CureMatch and CureMatch with QCI, respectively, and the obtained treatment recommendations differed drastically. Conclusions Treatment decisions based on molecular markers appear at present to be arbitrary and dependent on the chosen strategy. As a consequence, tumours with identical molecular profiles would be differently treated, which challenges the promising concepts of genome-informed medicine
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
Background
Patients with prostate cancer may present with metastatic or recurrent disease despite initial curative treatment. The propensity of metastatic prostate cancer to spread to the bone has limited repeated sampling of tumor deposits. Hence, considerably less is understood about this lethal metastatic disease, as it is not commonly studied. Here we explored whole-genome sequencing of plasma DNA to scan the tumor genomes of these patients non-invasively.
Methods
We wanted to make whole-genome analysis from plasma DNA amenable to clinical routine applications and developed an approach based on a benchtop high-throughput platform, that is, Illuminas MiSeq instrument. We performed whole-genome sequencing from plasma at a shallow sequencing depth to establish a genome-wide copy number profile of the tumor at low costs within 2 days. In parallel, we sequenced a panel of 55 high-interest genes and 38 introns with frequent fusion breakpoints such as the TMPRSS2-ERG fusion with high coverage. After intensive testing of our approach with samples from 25 individuals without cancer we analyzed 13 plasma samples derived from five patients with castration resistant (CRPC) and four patients with castration sensitive prostate cancer (CSPC).
Results
The genome-wide profiling in the plasma of our patients revealed multiple copy number aberrations including those previously reported in prostate tumors, such as losses in 8p and gains in 8q. High-level copy number gains in the AR locus were observed in patients with CRPC but not with CSPC disease. We identified the TMPRSS2-ERG rearrangement associated 3-Mbp deletion on chromosome 21 and found corresponding fusion plasma fragments in these cases. In an index case multiregional sequencing of the primary tumor identified different copy number changes in each sector, suggesting multifocal disease. Our plasma analyses of this index case, performed 13 years after resection of the primary tumor, revealed novel chromosomal rearrangements, which were stable in serial plasma analyses over a 9-month period, which is consistent with the presence of one metastatic clone.
Conclusions
The genomic landscape of prostate cancer can be established by non-invasive means from plasma DNA. Our approach provides specific genomic signatures within 2 days which may therefore serve as 'liquid biopsy'
- …